Objectives: To investigate whether docosahexaenoic acid (DHA) supplementation was able to ameliorate attention-deficit/ hyperactivity disorder(AD/HD) symptoms in AD/HD children. Design and subjects: A placebo-controlled double-blind study with 40 AD/HD (including eight AD/HD-suspected) children of 6-12 y of age who were mostly without medication. Subjects of a DHA group (n ¼ 20) took active foods containing fish oil (fermented soybean milk, bread rolls and steamed bread; 3.6 g DHA/week from these foods) for 2 months, whereas those of a control group (n ¼ 20) took indistinguishable control foods without fish oil. The following items were measured at the start and end of the study: (1) attention deficit, hyperactivity and impulsivity (AD/HD-related symptoms according to DSM-IV criteria); (2) aggression assessed by both parents and teachers; (3) visual perception (finding symbols out of a table); (4) visual and auditory short-term memory; (5) development of visual-motor integration; (6) continuous performance; (7) impatience. Results: Changes in tests 1, 2, 3, 5 and 7 over time did not significantly differ between the two groups. However, visual shortterm memory and errors of commission (continuous performance) significantly improved in the control group compared with the changes over time in the DHA group (P ¼ 0.02 and 0.001, respectively). Recalculation without AD/HD-suspected subjects (n ¼ 4 each group) showed similar P-values with regard to both measures. Conclusion: DHA supplementation did not improve AD/HD-related symptoms. Treatment of ADHD with fatty acids deserves further investigation, but careful attention should be paid as to which fatty acid(s) is used.
Introduction
Attention-deficit/hyperactivity disorder (AD/HD) is one of the most important chronic neuronal disorders in childhood. Patients with AD/HD are inattentive, impulsive and/or hyperactive. Those behaviors may harm school performance and family relationships. The etiology of the disorder is not determined yet (Wilens et al, 2002) . Stimulant drugs are a well-known treatment method and are able to relief symptoms of AD/HD (Rapport et al, 1994; Goldman et al, 1998) ; however, there is no consensus over long-term uses of the drugs, and their adverse effects still need to be evaluated (Brue & Oakland, 2002) . This is one of the important reasons why complimentary and alternative medical therapies are popular. If they are safe and effective, they might be a great help. Unfortunately, not many complimentary and alternative methods have been carefully assessed (Arnold, 1999) .
Comparing 48 hyperactive children with 49 age-and sexmatched controls, Mitchell et al (1987) reported that the levels of docosahexaenoic (DHA), dihomo-g-linolenic and arachidonic (AA) acids were significantly lower (about À15%) in the serum phospholipid fraction in hyperactive children than controls. Stevens et al (1995) analyzed fatty acid metabolism measuring the lipids of plasma and red blood cells of 53 AD/HD subjects. They found that DHA and AA were significantly reduced in the AD/HD subjects than in controls both in the plasma polar lipid fraction and in the total lipid fraction of red blood cells. The degrees of reduction in DHA in the AD/HD children were more or less twice greater than in AA. This may imply the possibility that DHA supplementation might reduce symptoms of AD/HD subjects. Voigt et al (2001) reported a randomized, doubleblind, placebo-controlled intervention study with 345 mg DHA/day for 4 months using 54 AD/HD children of 6-12 y of age as subjects. Unfortunately, the results were not encouraging; no symptoms of AD/HD were reduced by DHA administration. In contrast, there is a possibility that supplementation of both n-3 and n-6 PUFA improved AD/ HD symptoms (Burgess, 1998) . However, the above report has not yet been available in a full paper. AD/HD-related symptoms in children with specific learning difficulties (mainly dyslexia), who also showed AD/HD features, were improved in a double-blind test after 12-week supplementation of a highly unsaturated fatty acid mixture (Richardson & Puri, 2002) .
In the present study we employed a higher dose of DHA, that is, 3600 mg/week, using 40 AD/HD children (including eight AD/HD-suspected subjects). Most of them (34 subjects) were drug-free in contrast to the study of Voigt et al (2001) .
Methods
Subjects and randomization A total of 40 school children (6-12 y of age) were recruited for the present study from a summer camp for children with psychiatric disorders run by one of the authors (SH). The summer camp consisted of 68 children of 3-15 y of age, about 90% of whom suffered from AD/HD as the major disorder. In this group, there were 46 AD/HD children of 6-12 y of age. We asked parents of those 46 children to participate in the present study, and 40 of them agreed (Figure 1 ). These 40 subjects had been diagnosed or suspected as AD/HD according to DSM-IV and diagnostic interviews including behavior observation by psychiatrists. In a strict sense, eight subjects might not be AD/HD according to the DSM-IV criteria, but two psychiatrists attending the summer camp strongly suspected them as AD/HD. Those 40 subjects were stratified according to their sexes and ages (equal to or below the third grade of their elementary schools, or above the third grade) and randomly assigned to either a control group or a DHA group in a double-blind manner by a third party using a phone book as a table of random numbers. The characteristics of subjects of the two groups are shown in Table 1 . Six subjects had been under medications (see Table 1 ). The two groups of subjects without AD/HD-suspected subjects (n ¼ 16 each) did not differ significantly with respect to sex or age. It was also the case with the two groups of subjects without medication (n ¼ 16 and 18 in the control and DHA groups, respectively). Comorbid conditions were slightly worse in the control group than in the DHA group, but none of the rates of the There were no significant differences between the two groups (w 2 test).
a Two in the DHA group were treated with methylphenidate alone, whereas four in the control group were under the following medications: methylphenidate in one, methylphenidate and risperidone in a second, carbamazepine and fluvoxamine in a third and carbamazepine and sulpiride in the last subject.
comorbid disorders listed in Table 1 were significantly different between the two groups. The present study was approved by the ethics committee of Toyama Medical and Pharmaceutical University, and written informed consent was obtained from a parent of each subject.
Test foods and administration
Subjects in the DHA group took fermented soybean milk (600 mg DHA/125 ml, 3/week), bread rolls (300 mg DHA/ 45 g, 2/week) and steamed bread (600 mg DHA/60 g, 2/week) for 2 months. As a total, their average intake of n-3 fatty acids from those foods was 3600 mg DHA þ 700 mg eicosapentaenoic acid (EPA)/week. Those in the control group took indistinguishable placebo foods containing olive oil instead of DHA-rich fish oil. The tastes of fish in active soybean milk were masked by special flavors, which cancelled fish odor; in case of the other active foods, fish oil was emulsified with fruit juice for masking. The third party written above sent the test foods with identical containers and wrappings to study subjects. Subjects' parents were asked to continue their habitual diet except that their children might reduce bread consumption.
Psychological measurements
The following items were measured at the start and end of the study:
(1) Assessment of attention deficit, hyperactivity and impulsivity was made according to AD/HD-related symptoms criteria of DSM-IV. Rating was performed by both parents and teachers of subjects. Scores were counted only when both of them gave the same assessment.
(2) Two questions were employed to assess aggression: (1) Does he/she easily become angry/hostile? and (2) Does he/ she push, pat, kick other people or pull other people's hair? Rating was performed by both parents and teachers of subjects. Scores were counted only when both of them gave the same assessment.
(3) Visual perception was scored according to Development Test of Visual Perception originally developed by Frostig et al (1966) with slight modifications. First, a tester indicated a symbol to look for to a subject, and asked him/ her to find as many identical symbols as possible out of a table of 8 Â 10 symbols including some identical ones within 60 s.
(4) Visual and auditory short-term memory was assessed by checking subjects' memorizing ability right after they looked at seven-digit numbers for 10 s and listened to seven-digit numbers, respectively (Miller, 1956) . Average scores in healthy subjects were reported to be around 3 in 4-y-old children and 6 in children of 10-12 y of age (Hulme & Mackenzie, 1992) .
(5) Developmental test of visual-motor integration (Beery, 1967) : The tester asked a subject to copy certain figures in the fixed order. Scores were normalized according to his/her chronological age with 100 as a standard.
(6) Continuous performance test: In this test, one of the nine digits (1-9) was shown on the computer display for 4 s, and replaced with another digit. Subjects were asked to push a button only when there was the sequence of 9 after 1. The following three numbers were counted: responses before second numbers appeared, errors of omission and errors of commission (Corkum & Siegel, 1993) .
(7) Impatience test: In this test, impulsivity was measured according to our original method. Subjects were asked to answer very simple questions only after their cue was given 2 s after the end of the question. Impulsivity was counted if answers were made before the cues.
Tests 3-7 were performed by the same tester during the present study.
Of the six subjects under medical treatment, four were tested before they were administered with drugs at both the start and end of the present study, but two (one with methylphenidate in the DHA group and another with carbamazepine and sulpiride in the control group) were tested after administration.
Statistical analysis
Data are expressed as medians (25 percentile, 75 percentile). Statview (Japanese version 5; SAS Institute Inc., CA, USA) was used for statistical analysis. Power calculations were made on the assumption that the effect size (d) was about 0.9 for changes in aggression by DHA administration (Hamazaki et al, 1996) . Then we would need 21subjects in each group to obtain a significant (Po0.05) result with an 80% probability. However, this calculation was only a rough estimate, because reference data came from healthy young adults (Hamazaki et al, 1996) , not AD/HD children. As most of the data obtained in the present study were not normally distributed, nonparametric methods were used. Wilcoxon matched pairs signed-rank test was used for intragroup comparisons. Intergroup differences were analyzed by Mann-Whitney's U-test with baseline as covariate. Baseline values were compared using Mann-Whitney's U-test or w 2 method.
Differences with Po0.05 were considered significant.
Results
All the subjects completed the present study. There were no complaints about the taste of control and DHA foods; consumption of both foods was nearly 100% according to a questionnaire performed at the end of the study. Results of the tests performed in the present study are shown in Table 2 and Figure 2 . None of the baseline values were significantly different between the two groups. Visual short-term memory (Figure 2a ) was significantly improved in the control group, whereas not in the DHA group, with a significant difference between the two groups. The results without the two subjects who took medicine even on the days of tests or without the six subjects who regularly took medicines (see the section of subjects) changed neither the general trend of test scores shown in Figure 2 nor P-values to any perceptible degrees. It was also the case with regard to the deletion of AD/HD-suspected subjects (n ¼ 4 each group).
Numbers of errors of commission (Figure 2b ) decreased significantly in the control group, and tended to increase in the DHA group, with a significant difference between the two groups. As in the case of visual short-term memory, P-values did not change markedly even after the deletion of the six subjects with medication or the eight AD/HDsuspected subjects.
Discussion
The most important finding of the present study is that performance of the subjects in the DHA group was not improved compared with the control group. Actually errors of commission in the continuous performance test (Corkum & Siegel, 1993) and visual short-term memory (Miller, 1956) in the control group significantly improved over time probably by learning effect, which was not paralleled by the DHA group. We included memory tests on the presumption that if DHA improved subjects' behavior, attention in particular, it would improve apparent power of memory. Unfortunately, the results were against our anticipation.
We had 40 subjects at the start of the study, and everyone completed the study, which was rather unusual in a study of this type. One of the reasons of this null dropout rate was probably the tastes of test and placebo foods. We recently experienced a similar result from a fish oil administration trial; in a placebo-controlled, double-blind test with 41 adult subjects using identical fermented soybean milk as a vehicle of fish oil , there were no dropouts, and most of the subjects liked its taste. Another reason was a shorter period of the study, that is, 2 months, instead of 3-4 months employed in other trials (Voigt et al, 2001; Richardson & Puri, 2002) . However, the most important reason might be that one of the present authors (SH) was in solid rapport with families of AD/HD subjects, most of whom had, in fact, attended the summer camp repeatedly.
At present it is not clear why there were significant differences in visual short-term memory and errors of commission as shown in Figure 2 . However, noradrenaline might be the key issue here and worth commenting. The main mechanism of psychostimulants is likely to depend upon a release of noradrenaline from sympathetic nerve endings and chromaffin cells (Rothman et al, 2001; Cooper et al, 2003) , and upon activation of the noradrenergic system in the brain, which in turn modulates higher cortical functions including attention (Biederman & Spencer, 1999) . We have already reported that DHA administration for two mon reduced plasma noradrenaline concentrations in healthy students who were under a chronic stressor Rating by both parents and teachers Mean numbers of symptoms according to DSM-IV Attention deficit 8 (6, 10) 8 (4, 10) 11 (7.5, 14.5) 12 (6, 16) Hyperactivity 2 (1.5, 6) 2 (0, 5) 2 (0, 6) 2 (2, 4) Impulsivity 2 (0, 2.5) 1 (0, 2) 0 (0, 4) 0 (0, 4) Aggression (our original questionnaire) 0 (0, 3) 0 (0, 2) 1 (0, 4) 0 (0, 2) 0.053 Rating by the same tester Attention (Frostig et al, 1966) Numbers of correct answers 4.5 (3, 7.5) 15 (5, 18) 0.001 4 (3, 7) 10 (4, 13) 0.02 Short-term memory (Miller, 1956) Visual (numbers of items remembered) 3.5 (2, 6) 5 (3, 7) 0.02 2.5 (1, 6) 3 (2, 4) 0.02 Auditory (numbers of items remembered) 2 (1, 2.3) 2 (1, 3) 0.09 2 (1, 3) 2 (1, 2) 0.07 Visual-motor integration (Beery, 1967) Normalized (Corkum et al, 1993) Responses before second numbers appeared 0 (0, 5. The values of the DHA group tended to be lower that those of the control group (P=0.06). Otherwise, there were no significant differences in baseline values between the two groups.
Intervention study of AD/HD with DHA rich fish oil S Hirayama et al (Sawazaki et al, 1999) . Very recently we found the same effects of EPA plus DHA in a double-blind study with 22 healthy students (unpublished data). Judging from the aggression-controlling effects of DHA found in normal people (Hamazaki et al, 1996 , DHA may also depress the central noradrenergic system that plays an important role in aggression (Haller et al, 1998) . Consequently, it might be possible that DHA exerted the exactly opposite influence of psychostimulants on AD/HD subjects and nullified learning effect through deterioration of attention. The ratio of DHA to EPA in the active test foods was about 5:1, mostly DHA. Did EPA contained in the active test foods exert any effects on the symptoms of AD/HD? DHA appears to differ considerably from EPA in terms of effects on the tissue fatty acid composition. Pure DHA intake increased both DHA and EPA in the phospholipid fraction of polymorphonuclear leukocytes in healthy volunteers, whereas pure EPA intake increased EPA but actually decreased DHA levels in the phosphatidylethanolamine fraction, the major DHA-rich fraction, in leukocytes (Terano et al, 1987) . In this context, the presence or absence of a small amount of EPA contained in the active foods was not likely to affect the fatty acid composition of tissues, since DHA intake increases both DHA and EPA at any rate.
Noradrenaline reuptake inhibitors are sometimes used in depressive patients. It was recently reported that the administration of pure EPA was beneficial for treatment of major depression (Nemets et al, 2002) , but DHA was not effective (Marangell et al, 2003) . Peet and Horrobin (2002) also reported the beneficial effects of pure EPA on major depression. Taken together, there is a possibility that pure EPA, which does not increase or even decreases the tissue DHA levels, may not decrease the central noradrenaline concentrations. Now we have an interesting open question: what if pure EPA is used for AD/HD children instead of DHArich fish oil or pure DHA. This remains to be investigated.
As shown in Table 1 , most of the subjects in the present study were without medication. Actually, deletion of the data of those who were regularly taking medicine (four in the control group and two in the DHA group) did not affect the results to any appreciable extent. This is in good contrast to the subjects used in the trial performed by Voigt et al (2001) . Their subjects were all taking psychostimulants during the study period except for the 24 h before administration of the laboratory measures. Psychostimulants that their subjects were using were all supposed to be washed out within 24 h (Voigt et al, 2001) . Consequently, our hypothesized noradrenaline-lowering effects of DHA were probably not overcome with psychostimulants when their DHA subjects were tested. Interestingly, errors of omission (a simple measure of inattention of the Test of Variables of Attention) performed in their study significantly increased in their DHA group, although there were no significant differences between the DHA and control groups (Voigt et al, 2001) . Aman et al (1987) investigated the effects of evening primrose oil on hyperactive children in a double-blind, placebo-controlled crossover study. They succeeded in enhancement of the serum levels of dihomo-g-linolenic acid during the evening primrose period, but could hardly show any benefit. Richardson and Puri (2002) reported beneficial effects of the mixture of polyunsaturated fatty acids (186 mg EPA, 480 mg DHA, 96 mg g-linolenic acid, 864 mg linoleic acid and 42 mg AA per day) on AD/HD-related symptoms in children with specific learning difficulties. Their subjects were 8-12 y old and all had literacy problems. They also had pretrial scores that were above population average on three parent rating scales designed to assess AD/HD-related symptoms according to DSM-IV criteria, although their subjects had not been diagnosed as AD/HD before. Since their study subjects did not suffer from AD/HD (Richardson & Puri, 2002 ), simple comparison is not possible. Addition of n-6 fatty acids might affect behaviors of AD/HD children. However, this should be carried out with caution, because (Miller, 1956) . (b) Numbers of errors of commission (Corkum et al, 1993) . Similar P-values were observed even after deletion of the eight AD/HD-suspected subjects shown with broken lines or of the six subjects taking medication in both parameters (a) and (b).
Intervention study of AD/HD with DHA rich fish oil S Hirayama et al linoleic acid intakes have already been above the optimal ranges these years (Hamazaki & Okuyama, 2003) , and AA intakes are positively related to the degree of inflammation (Adam et al, 2003) .
The use of olive oil as a placebo in the present study might not be a good choice, because it might affect mood disorder (Puri & Richardson, 2000) . Considering the amount of olive oil used in the placebo group (less than 9 g/week in the control foods) and a huge amount of oleic acid (the main component of olive oil) reserve in the adipose tissue, it is likely that the effect of the placebo oil was negligible.
As mentioned in the introduction, the fatty acid composition in blood samples of AD/HD subjects was reported to be different from normal subjects. We tried to take blood samples in the present study, but gave up the idea of blood sampling because it was difficult to obtain consent from parents. Consequently, it is still unclear whether or not Japanese AD/HD children, who are supposed to have more fish than children in other countries, are essential fatty aciddeficient. In our previous randomized controlled trial with children, in which we used bread, spaghetti and sausage containing the same amount of DHA (3.6 g/week as a total), it was confirmed that EPA and DHA levels in RBC were increased by 14% in the DHA group (Itomura et al, 2002) . Therefore, it is likely that DHA levels in the subjects in the present study also increased to a similar extent.
In Japan many parents think that their children should not take medication regularly, especially when they are very young. This trend was also apparent in the present study; only six out of the 40 participants were taking medication, and those six were all above 9 y of age. This is in remarkable contrast with the study of Voigt et al (2001) . In order to determine if DHA-rich fish oil could reduce AD/HD symptoms, a study with capsules might have been simpler and less confounded. Taken into account that even normal foods, like milk, soy, peanut butter or wheat, can provoke AD/HD symptoms (Carter et al, 1993) , the vehicles used in the present study (bread, spaghetti and fermented soybean milk) might have exerted a confounding effect. However, we are very sure that most parents of the AD/HD children in the present study would not have agreed to participate in the study if capsules had been used instead, because they look very much like medication. Although the diet of the study subjects was likely to change more than in case of capsule administration, it is considered that the comparison between the effects of DHA-rich fish oil and placebo oil was still properly performed. The vehicles used in the present study apparently did not deteriorate any measures in the control group.
We have already reported aggression-controlling effects of DHA (Hamazaki et al, 1996 . However, in the present study, there was only a downward trend of aggression in the DHA group. In our recent randomized controlled study (Itomura et al, 2002) , physical aggression of normal school children of 9-12 y of age was rated by themselves. It was found that there were significant differences in changes in physical aggression over time between the DHA and control groups in favor of the DHA group. In the present study, aggression, which was rated by parents and the teachers of subjects instead of the subjects themselves, and counted only when both of them gave the same assessment, did not significantly change between the two groups. Questionnaires to the study subjects themselves might have produced different results. However, questionnaires to AD/HD subjects were not practical because of their ages and inability to cooperate.
Recently Gesch et al (2002) performed a double-blind, placebo-controlled, randomized trial with 231 young adult prisoners for a minimum of 2 weeks. One group of prisoners were given nutritional supplements containing vitamins, minerals and essential fatty acids and were compared with the other group with placebos with regard to antisocial behavior. Compared with the placebo group, those receiving active supplements committed an average of 26.3% fewer offences. Although active supplements contained EPA and DHA, the daily intakes from the supplements were only 80 mg EPA and 44 mg DHA, much smaller than the dosage of the present study. The study of Gesch et al (2002) suggests that a combination of nutrients might work effectively. However, it is impossible to determine which factors were effective from their study. It might be that different factors are important for different prisoners. From the present study, it is suggested that DHA alone did not improve AD/HD.
In conclusion, DHA supplementation did not improve any AD/HD symptoms. Treatment of ADHD with fatty acids deserves further investigation, but careful attention should be paid as to which fatty acid(s) is used.
